LFS after HSCT and OS
| . | no. (%) or median (range) . |
|---|---|
| LFS after HSCT, n = 17* | |
| Patients who were leukemia-free | 14 (82) |
| Post-HSCT relapse | 2 (12) |
| HSCT-related deaths | 1 (6) |
| Follow-up time from HSCT, mo | 23.8 (7.0-39.3) |
| OS, n = 18 | |
| Patients alive | 16 (90) |
| Follow-up time from C1D1, mo | 26.9 (18.2-44.4) |
| . | no. (%) or median (range) . |
|---|---|
| LFS after HSCT, n = 17* | |
| Patients who were leukemia-free | 14 (82) |
| Post-HSCT relapse | 2 (12) |
| HSCT-related deaths | 1 (6) |
| Follow-up time from HSCT, mo | 23.8 (7.0-39.3) |
| OS, n = 18 | |
| Patients alive | 16 (90) |
| Follow-up time from C1D1, mo | 26.9 (18.2-44.4) |
C, cycle; D, day.
17 patients who received HSCT; 1 nonresponding patient died prior to HSCT.